SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom (AVGO) is trending following strong Q4 earnings and an upbeat Q1 revenue forecast, driven by booming AI chip demand. The community is focused on whether AVGO's earnings call can sustain the positive momentum, especially after market concerns were raised by Oracle's recent report, with some anticipating a significant price movement post-call. Investors are weighing the company's AI prospects against valuation concerns, with comparisons to NVDA's market capitalization and revenue multiples being actively discussed.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors react to earnings news and a surprise CEO departure, with community members debating whether the results justify the stock's surge. Bullish sentiment highlights a potential turnaround and strong China sales, while bears cite valuation concerns and leadership uncertainty. The stock's movement is also drawing comparisons to other retail companies and potential sector-wide recovery.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading day, driven by a recently announced $40M offering that sparked a sharp sell-off, overshadowing positive Q3 results. The community is debating the offering's impact, potential for a dead cat bounce, and whether it's a buying opportunity or a sign of further decline. Some traders are drawing parallels to other high-flying stocks, while others remain optimistic about MIGI's long-term prospects in the digital infrastructure space.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

ALT is trending amid mixed sentiment, with some community members expressing concerns about trial data and potential delays, using hashtags like #endpointfailures and #delays. Meanwhile, other investors remain bullish, emphasizing the potential of their drug and dismissing bearish arguments, while awaiting key data releases and FDA feedback. Discussions include the impact of PathAI approval and speculation around potential partnerships.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as investors digest its latest earnings report, which revealed a revenue miss despite a beat on EPS. Community discussions are centered on the company's guidance and whether the results are strong enough to attract bulls amidst a cautious market tape.  Some analysts suggest the company's valuation is disconnected from modest growth rates, while others point to robust membership revenue and market share gains.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RH (Restoration Hardware) is trending due to mixed reactions surrounding its earnings call and future guidance, with some questioning the CEO's commentary. The community is actively discussing the potential impact of tariffs and interest rate decisions on the luxury home furnishings sector. Bullish investors are anticipating a short squeeze, while bearish investors are pointing to a potential price drop.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending amid analyst upgrades and community speculation about upcoming catalysts, including a presentation at the Barclays Global Technology Conference. Community members are actively debating the potential for a short squeeze, while also discussing the company's fundamentals and competition in the AI sector. Recent news of partnerships and integrations is adding to the buzz, with bulls hoping for a sustained upward move.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending due to strong community support and momentum, with many highlighting its potential as the next big meme coin on the Ethereum network. Bullish sentiment is fueled by comparisons to $PEPE and $DOGE, and references to a long-term prophecy, while some community members also suggest smart money is accumulating the token.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the market eyes new all-time highs, fueled by anticipation around Broadcom's earnings and the potential impact on AI-driven stocks. Community chatter reflects a battle between bulls and bears, with debates over market manipulation and the sustainability of the current rally. Some traders are expressing concerns about overvaluation and potential corrections, while others remain optimistic, pointing to the Fed's actions and overall market momentum.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it prepares to host its first Autonomy and AI Day, where the company is expected to reveal details about its self-driving technology and in-house AI capabilities. The community is buzzing with anticipation, while also debating the impact of potential delays in the R2 program and questioning the company's ability to compete with established players like Tesla. Some investors express concerns over cash burn and dilution, while others remain bullish, highlighting the potential for Rivian's technology and upcoming AI-driven features.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $1000 In Invesco NASDAQ 100 ETF Stock 5 Years Ago, You Would Have This Much Today

<ul class="summary-bullets"><li>In an update on Monday afternoon, the company said it is seeing signs of recovery for admin and POS login issues after deploying a fix for login issues at around 12:20 EST.</li><li>Later in the evening at around 17:00 EST, the company reiterated that they are continuing to monitor the recovery of the issue and will update once it has new information.</li><li>For Shopify, the outage coincided with Cyber Monday, a day of online sales that falls on the Monday after the U.S. Thanksgiving weekend. &nbsp; &nbsp;</li></ul> Shares of Shopify (SHOP) edged up 0.6% in after-hours on Monday as signs of recovery followed its Cyber Monday outage, even as the stock had closed the regular session down 6%.The Canadian e-commerce company said on Monday morning &nbsp;at around 9:47 EST that merchants may experience issues when trying to login to Shopify and also when logging into point-of-sale systems or attempting to contact support. A point of sale, or POS, is a system used to process transactions and accept payments in person.<h2 class="st-heading-2">Company Deploys Fix Over Hours</h2>In an update on Monday afternoon, the company said it is seeing signs of recovery for admin and POS login issues after deploying a fix for login issues at around 12:20 EST.“We have found and fixed an issue with our login authentication flow, and are seeing signs of recovery for admin and POS login issues now. We are continuing to monitor recovery,” the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shopifystatus.com/">said</a> in an update at 14:31 EST.Later in the evening at around 17.00 EST, the company reiterated that they are continuing to monitor the recovery of the issue and will update once it has new information.According to data from Downdetector, Shopify outage reports touched a high of over 4000 on Monday morning around 11:00 am EST before tapering down through the day. &nbsp;For Shopify, the outage coincided with Cyber Monday, a day of online sales that falls on the Monday after the U.S. Thanksgiving weekend. On Black Friday, the company’s global sales had hit $6.2 billion, up 25% from last year. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SHOP stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user highlighted that the day was one of their biggest revenue reaping ones. “I wonder how big the hit will be to the bottom line,” they wrote.<stembedurl>https://stocktwits.com/Timmiee/message/637837465</stembedurl><a href="https://stocktwits.com/symbol/SHOP">SHOP stock</a> has gained over 40% this year and by about 32% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/instagram-chief-wants-staff-to-return-to-office-full-time-report/cLI7oYXRE0d">Instagram Chief Wants Staff To Return To Office Full Time: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shopify topped analyst expectations on earnings and revenue while also announcing an upbeat forecast for the third quarter.

Shopify Stock Rises After Hours As Recovery Signs Emerge From Cyber Monday Meltdown

The Canadian e-commerce company said on Monday morning at around 9:47 EST that merchants may experience issues when trying to login to Shopify and also when logging into point-of-sale systems or attempting to contact support.

Equity

Detailed Fundamental Analysis - QQQM

Below is Validea's ETF fundamental report for Invesco NASDAQ 100 ETF (QQQM). The report looks at QQQM's exposure to the major investing factors including value, quality, momentum and low volatility...

QQQM ETF Factor Report

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary disease (COPD) did not achieve statistical significance in the primary endpoint of controlling flare-ups.COPD, also called Smoker’s Disease, is a debilitating, irreversible, and progressive disease whose exacerbations are life-threatening and can cause irreversible lung damage and even death. According to AstraZeneca, it affects 391 million people globally.The safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html">stated</a> that it will analyze the data further to understand the results.Shares of the company slipped 0.3% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:572/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_7_28_11_AM_png_b16313a518.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="572" height="62"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:28 a.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure> The study was aimed at evaluating the efficacy and safety of 100 mg of Fasenra in people with moderate to very severe COPD with a history of frequent COPD exacerbations and an elevated blood eosinophil count. The company enrolled patients in the trial with a history of at least two COPD exacerbations in the year before enrollment and who were current or former smokers. Patients were randomized to receive either a placebo or Fasenra while remaining on their existing therapy.“COPD, which remains a leading cause of death worldwide, is a complex, heterogeneous disease and we continue to advance other promising approaches in our pipeline to address the unmet needs of patients,” company executive Sharon Barr saidFasenra is already used to treat severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis in several countries. According to AstraZeneca, over 150,000 patients worldwide are currently taking Fasenra. In the first half of 2025, Fasenra generated $920 million in revenue, representing an 18% year-over-year increase.Separately, the company also <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-met-primary-endpoint-in-tulip-sc.html">announced</a> that its late-stage trial evaluating subcutaneous Saphnelo in patients with systemic lupus erythematosus (SLE) met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in disease activity compared to placebo. SLE is an autoimmune disease in which the immune system attacks healthy tissue in the body. It is estimated to impact over 3.4 million people globally.AZN stock is up by 18% this year and down by about 1% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/x4-pharma-to-halve-headcount-amid-efforts-to-complete-neutropenia-trial/chDGnJwRd6P">X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease

The company stated that the safety and tolerability of the drug in the recent trial were consistent with the known profile of the medicine, and added that it will analyze the data further to understand the results.

Marvell Technology (MRVL) plunged more than 17% at market open on Friday after issuing weaker-than-expected third-quarter guidance in its fiscal second-quarter report released late Thursday, which drew swift price target cuts and&nbsp;a ratings downgrade from Wall Street.<a href="http://stocktwits.com/symbol/MRVL">Marvell’s stock</a> was among the top trending tickers on Stocktwits at the time of writing. Despite the dip in its stock price, retail sentiment around the company surged to ‘extremely bullish’ from ‘bullish’ with chatter rising to ‘extremely high’ from ‘low’ levels over the past day, according to platform data.Bank of America downgraded&nbsp;Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90, as per TheFly. The firm cited uncertainty surrounding Marvell’s role in Microsoft’s (MSFT) Maia AI accelerator and its share of Amazon’s (AMZN) next-generation 3nm project.Morgan Stanley trimmed its target on the stock to $76 from $80 while keeping an ‘Equal Weight’ rating. The firm noted that while guidance was largely in line once the sale of Marvell’s automotive Ethernet business was factored in, the data center segment “disappointed.” Morgan Stanley added that it was not surprised by the business’s “lumpiness,” but said it was unexpected that the ASIC full-year outlook continues to decline even as demand for Amazon’s Trainium processors strengthens elsewhere.&nbsp;UBS, which lowered its price target to $95 from $110,&nbsp; also pointed to “lumpiness” in Marvell’s business.&nbsp;Needham echoed similar concerns about Marvell’s next-gen XPU contracts with Amazon and Microsoft as it lowered its price target to $80 from $85, but maintained its ‘Buy’ rating on the stock.Marvell’s stock has fallen more than 41% this year and is down around 7% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-revokes-intel-samsung-sk-hynix-waivers-on-china-chip-equipment/chtTKpgRdNh">US Revokes Intel, Samsung, SK Hynix Waivers On China Chip Equipment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Marvell Hit With Downgrade, Price Target Cuts As Analysts Flag Uncertainty In Microsoft, Amazon AI Deals

Bank of America downgraded Marvell’s stock to ‘Neutral’ from ‘Buy’, lowering its price target to $78 from $90.

3 Reasons Why Nasdaq ETFs Hit a Record High 

The Nasdaq hit a record high despite tariffs, as Apple's $100B U.S. push, Fed rate cut talks and chip exemptions fuel tech optimism.

Nasdaq ETF (QQQM) Hits New 52-Week High

QQQM surges to a new 52-week high, fueled by tech strength and AI-driven earnings momentum in Nasdaq.


Will Nasdaq ETFs Continue Their Rally Going Into Q2 Earnings?

QQQ, QQQM, QQEW, QQQJ and QQQE surge as Nasdaq hits highs on earnings momentum, AI optimism and rate cut hopes.

AstraZeneca (AZN) on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html">announced</a> a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat multiple chronic diseases.Under the deal, the companies have also agreed to develop a pre-clinical small-molecule oral therapy for immunological diseases.The research will be carried out by CSPC in Shijiazhuang City and will utilize their AI-driven drug discovery platform, which uses AI to analyse the binding patterns of target proteins with existing compound molecules. The AI also helps conduct targeted optimization with the intent of selecting highly effective small molecules with excellent developability.CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.CSPC can also receive potential single-digit royalties based on annual net sales of the products.AstraZeneca, meanwhile, will have the right to exercise options for exclusive licenses to develop and commercialize worldwide candidates identified under the agreement.In March, AstraZeneca announced a $2.5 billion investment in a research and development hub in Beijing. The new agreement will further the company’s presence in China, AstraZeneca said.On Stocktwits, retail sentiment around AstraZeneca stayed within the ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1260/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_7_54_25_AM_png_1341b85d61.webp" alt="AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1260" height="132"><figcaption>AZN's Sentiment Meter and Message Volume as of 7:54 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up by about 14% this year but down by nearly 6% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-launches-upgraded-model-s-x-in-us-raises-prices-5000-dollars/chlicMCRRGy">Tesla Launches Upgraded Model S, X In US, Raises Prices On All Variants By $5,000</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer

CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales milestone payments.

Invesco Exchange-Traded Fund Trust II - Invesco NASDAQ 100 ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$257.55
Prev Close	$258.39
Open	$256.84
Dividend Yield	N/A
50-Day Moving Average	$252.29
Beta	N/A
Avg. Volume	5.76M
PE Ratio	N/A

52-Week High	$262.23
52-Week Low	$165.72
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

QQQM
Invesco NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest QQQM News

QQQMInvesco NASDAQ 100 ETF